Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer

ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer

It also revealed that Keytruda cut the risk of disease progression or death by 40% compared to chemo, which is currently the standard treatment for these patients, and 48.3% of ... the patients on Merck’s drug lived without disease progression for two

Latest news

More from news
Approximately 1 fully matching, plus 280 partially matching documents found.

Latest Intelligence

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    Despite the significant anecdotal evidence, an initial study of Kaletra in China demonstrated some disappointing results; it did not seem to have any significant effect on disease progression. ... Infectious disease expert Lindsey R Braden and NEJM editor

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... If people are hoping for any of the molecules under investigation to be a

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    According to the study, the blood test is able to identify this protein 20 years before the symptoms of the disease start to present. ... Alzheimer’s R&D has had to diversify as companies and researchers become increasingly aware that the disease has a

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    applications in pharma and real-world ML/AI platforms for scalable disease diagnostics, progression and treatment. ... We’re going to work with the NHS to eliminate this disease in the UK.

  • The first, my last, my everything The first, my last, my everything

    In a widespread shift from volume to value, around 80% of molecules in development at present are in oncology or rare disease. ... In the past, industry has taken a traditional view of patient value, typically basing it on clinical outcomes and disease

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics